文献速递炎症性肠病

乌司奴单抗或维得利珠单抗在妊娠期IBD患者中的安全性:多中心队列研究

Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2020-12-07

该多中心回顾性队列研究分析了68例IBD孕妇的73次妊娠,其中乌司奴单抗组29次妊娠活产率90%,维得利珠单抗组44次妊娠活产率86%,并与88次抗TNF暴露妊娠对照。两组早产、自然流产、先天畸形及母体并发症发生率与抗TNF组相当,未发现母婴不良结局信号。

要点

  • 乌司奴单抗和维得利珠单抗妊娠期暴露未显示母婴不良结局信号
  • 两组活产率分别为90%和86%,与抗TNF对照组并发症率相当
  • 乌司奴单抗/维得利珠单抗组既往暴露>2种抗TNF比例显著高于对照组

核心结论

  • 妊娠期使用乌司奴单抗或维得利珠单抗未观察到母体或新生儿不良结局的负面信号。

研究设计与样本

  • GETAID中心开展的多中心回顾性队列研究,纳入妊娠期或孕前2个月内接受乌司奴单抗或维得利珠单抗的IBD孕妇,对照为妊娠期暴露抗TNF的IBD孕妇。
  • 共分析68例IBD孕妇的73次妊娠,其中乌司奴单抗29次、维得利珠单抗44次;对照组为76例IBD孕妇的88次妊娠。

主要发现

  • 乌司奴单抗组29次妊娠中26次(90%)活产、2次(7%)自然流产、1次(3%)择期终止。
  • 维得利珠单抗组44次妊娠中38次(86%)活产、5次(11%)自然流产、1次(3%)医学终止。
  • 乌司奴单抗和维得利珠单抗组既往暴露>2种抗TNF的患者比例分别为22%和10%,显著高于对照组的3%(P < 0.005)。
  • 两组早产率、自然流产率、先天畸形率及母体并发症发生率与抗TNF对照组相当。
  • 受孕时中位年龄、吸烟比例及受孕时临床活动度在各组间可比。

临床怎么用

  • 对于妊娠期或孕前需使用乌司奴单抗或维得利珠单抗的IBD患者,现有数据未提示母婴不良结局风险增加,可作为抗TNF之外的考虑选项。
  • 临床决策仍需结合个体病情及药物暴露史,尤其注意既往多种抗TNF暴露者。

局限性

  • 本研究为回顾性队列研究,样本量有限。
  • 原文指出需进一步开展前瞻性研究评估新型生物制剂妊娠结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of inflammatory bowel diseases (IBD) is high in women of childbearing age. Achieving clinical remission from conception to delivery using current medications is a major issue in IBD. AIMS: To assess maternal and neonatal complications and management of vedolizumab or ustekinumab) in pregnant women with IBD receiving these agents. METHODS: We performed a retrospective cohort study among GETAID centres including women with IBD who received ustekinumab or vedolizumab during pregnancy or within the 2 months before conception and compared outcomes to women exposed to anti-TNF treatment during pregnancy. RESULTS: Seventy-three pregnancies in 68 women with IBD were analysed: 29 on ustekinumab resulting in 26 (90%) live births, two (7%) spontaneous abortions and one (3%) elective termination; 44 on vedolizumab resulting in 38 (86%) live births, five (11%) spontaneous abortions and one (3%) medical interruption. The control group included 88 pregnancies exposed to anti-TNF in 76 women with IBD. The median age at conception, the proportion of women who smoked or in clinical activity at conception was comparable between groups. Only the proportion of patients exposed to >2 anti-TNF agents was significantly increased among the ustekinumab and vedolizumab groups compared to control group (22% and 10% vs 3%, P < 0.005). Rates of prematurity, spontaneous abortion, congenital malformations and maternal complications were comparable between groups. CONCLUSION: We report 73 pregnancies in patients receiving vedolizumab or ustekinumab without a negative signal on maternal or neonatal outcomes. Further prospective studies are needed on the outcomes of pregnancies with new biologic drugs.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wils P, Seksik P, Stefanescu C, et al. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Aliment Pharmacol Ther. 2020. PMID: 33345331. doi:10.1111/apt.16192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。